Molecular Pathology of Lung Cancer

Area of Science:

• Oncology
• Genomics
• Pathology

Background:

• Targetable genomic alterations are crucial for guiding lung cancer therapy.
• The field of molecular and biomarker testing in lung cancer is rapidly advancing.
• Pathologists face challenges in utilizing small lung cancer specimens for ancillary molecular testing.

Purpose of the Study:

• To highlight the importance of identifying targetable genomic alterations in lung cancer.
• To inform pathologists about specimen requirements, testing methodologies, and key targets for molecular testing.
• To emphasize the role of guideline statements in optimizing ancillary molecular testing.

Main Methods:

• Review of current guideline statements on molecular testing in lung cancer.
• Discussion of best practices for ancillary molecular testing on small biopsy specimens.
• Identification of essential genomic targets for lung cancer therapy selection.

Main Results:

• Standard of care requires identification of targetable genomic alterations for therapy selection.
• Pathologists need awareness of testing protocols and targets for clinical decision-making.
• Existing guidelines assist in maximizing the utility of small lung cancer specimens.

Conclusions:

• Accurate genomic profiling is essential for personalized lung cancer treatment.
• Adherence to guidelines ensures optimal use of molecular testing in pathology.
• Informed testing practices lead to clinically relevant genomic information for patient care.